Can we finally modulate post-stroke inflammation? 🧠

The EMPHASIS trial (Lancet 2026) randomized 1,724 patients with acute ischemic stroke to short-course oral minocycline within 72h.

Result: higher rates of excellent 90-day outcome (mRS 0–1 52.6% vs 47.4%; RR 1.11, p=0.0061) without safety concerns.

A cheap, generic drug showing signal in late neuroprotection.

Inflammation may not just follow stroke — it may shape recovery. 🔬